Source comparison
Difference Between Ipamorelin and Tesamorelin: Research Application Comparison
Primary Mechanism Ghrelin receptor (GHS-R1a) agonist producing pulsatile GH secretion GHRH receptor agonist producing sustained GH elevation with visceral fat selectivity Ipamorelin mimics natural GH pulses; Tesamorelin produces pharmacological GHRH stimulatio
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Ghrelin receptor (GHS-R1a) agonist producing pulsatile GH secretion
- GHRH receptor agonist producing sustained GH elevation with visceral fat selectivity
- Ipamorelin mimics natural GH pulses; Tesamorelin produces pharmacological GHRH stimulation
- Receptor Selectivity
- High selectivity for GHS-R1a; minimal ACTH or prolactin receptor binding
- Exclusive GHRH receptor binding; no ghrelin pathway interaction
- Non-overlapping receptor profiles mean distinct experimental use cases
- Half-Life
- Approximately 2 hours in circulation
- Approximately 26–38 minutes (extended by hexenoyl-albumin binding)
- Both require daily dosing in research protocols despite different clearance rates
- Documented Clinical Effect (Visceral Fat)
- Modest indirect effect through GH-mediated lipolysis
- 15.2% visceral adipose area reduction over 26 weeks (phase III data)
- Tesamorelin shows superior visceral fat targeting in published trials
- Cortisol/Prolactin Impact
- Minimal to none in preclinical models
- Minimal; no significant ACTH or prolactin elevation in phase II/III trials
- Both avoid the cortisol spikes seen with earlier-generation secretagogues
- Storage Stability (Reconstituted)
- 28 days at 2–8°C
- 14–21 days at 2–8°C due to larger molecular structure
- Ipamorelin offers longer post-reconstitution stability for extended protocols